Navigation Links
Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
Date:10/3/2007

BUENOS AIRES, Argentina, October 3, 2007 The first reported findings from an international, Phase 3 study showed that more than two-thirds of patients with moderate to severe plaque psoriasis receiving two doses of ustekinumab (CNTO 1275) achieved at least a 75 percent reduction in psoriasis at week 12, the primary endpoint of the study, as measured by the Psoriasis Area and Severity Index (PASI 75). Importantly, findings also showed that following one additional dose at week 16, a substantial proportion of patients receiving ustekinumab maintained a PASI 75 response through week 28. Data from the study, presented at the World Congress of Dermatology, involved more than 1,200 subjects and showed that within four weeks of initiating treatment with ustekinumab, patients experienced significant and clinically meaningful improvements in quality of life measures compared with patients receiving placebo. Ustekinumab is a new, fully-human monoclonal antibody with a novel mechanism of action that targets the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), and is currently in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis.

These data, presented at the 21st meeting of the World Congress of Dermatology, will be the subject of a live press briefing and webcast (www.cnto1275wcd.com) today at 2 p.m. EDT featuring Craig Leonardi, MD, St. Louis University Medical School, St. Louis, MO, Kristian Reich, MD, Georg-August-University, Gttingen, Germany, Silvia Fernandez Barrio, executive director, Civil Association of Psoriasis Patients of Argentina, Buenos Aires, Argentina, and Tom Schaible, PhD, vice president, Medical Affairs, Centocor, Inc.

These findings provide further evidence of the role of IL-12/23 in the pathogenesis of psoriasis and the promise that a new therapeutic approach like ustekinumab may hold for dermatologists and their patients living w
'/>"/>

Contact: Michael Parks
215-325-4010
Centocor, Inc.
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. PCR emerging as a promising technique for Diagnosing Urinary Tuberculosis
2. Experimental treatment for Ebola Virus Shows promising results in mice
3. Promising Treatment for Diabetes
4. A promising treatment for wart removal
5. Hepatitis shots is promising
6. Life after Bypass not so Promising for Women.
7. Promising cure for West Nile Virus
8. Deadly Diarrhoea Vaccine – Trail Results Promising
9. Novartis MS Drug Shows Promising Results
10. Sunitinib a Promising Agent for Treatment of Renal Cell Cancer
11. Research Ethics Requirements Compromising Quality of Health Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Residents in St. Petersburg, FL have a new ... David Sherberg, DMD, has joined Coast Dental Pasadena, located ... preventive, restorative and cosmetic dentistry to patients age 12 ... a wide variety of services including teeth ... bridges, dentures, dental implant restorations, veneers, laser therapy, oral ...
(Date:5/21/2013)... 21, 2013 Three major Ohio universities and four ... to establish a new collaborative research program aimed exclusively ... March of Dimes intends to invest $10 million in ... of Dimes Prematurity Research Center -- Ohio Collaborative is ... President of the March of Dimes. "This new transdisciplinary, ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Healthcare industry ... at the premier “Start Me Up” Emerging Healthcare Technology ... Education in Madison, Wisconsin. This new event is ... a gathering of national healthcare leaders being held June ... the University of Wisconsin. , Funding for healthcare information ...
(Date:5/21/2013)... Austin, TX (PRWEB) May 21, 2013 It’s ... off to summer camp or starting practice for summer or ... required before camp or sporting activities can begin. , ... an affordable option for youth sports or camp physicals ... MedSpring’s on-site doctors will review a child’s medical history, perform ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Everspark Interactive, ... firms, has been growing rapidly over the past year ... was hired to spearhead interactive marketing efforts for Kids ... , Everspark started as a local effort, specializing ... guiding search traffic to a company's website. The company ...
Breaking Medicine News(10 mins):Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 2Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 3Health News:New multi-million dollar research center aims to solve the mystery of premature birth 2Health News:New multi-million dollar research center aims to solve the mystery of premature birth 3Health News:“Start Me Up" Healthcare Conference: Where Healthcare CIOs, Entrepreneurs and Investors Meet 2Health News:MedSpring Offers Camp and Sports Physicals For $29 2Health News:Everspark Named Interactive Marketing Company for Kids II 2
... ward off obesity as children get older.// The ... data available on breastfeeding and weight of children ... at clarifying the situation. In both, investigators followed ... see how breastfeeding impacts weight. Detailed breastfeeding histories ...
... the rejection of being picked last for a sports team, ... or being turned down for a date. //Whatever the social ... in our heads. ,According to researchers, the brain seems ... same way ,as physical pain. To study this phenomenon, investigators ...
... for cancer complain of feeling weak //and tried, and ... symptoms. A new study suggests that may not be ... with worse prognosis after radiotherapy, the doctors assumed the ... of the therapy, as well., ,Not so, report ...
... complain of feeling weak and tired,// and doctors often ... new study suggests that may not be a good ... prognosis after radiotherapy, the doctors assumed the treatment would ... therapy, as well., ,Not so, report German researchers ...
... took the drug earlier than suggested may have done migraine ... the medication works best when taken at the first sign ... severe, as was the requirement of the original study., ... agonists for the treatment of migraine have required patients to ...
... shows drug-emitting stents are effective at keeping arteries open in ... coated with the drug sirolimus. It is an immunosuppressive agent. ... the artery from closing again.// ,Stents are used to ... very useful. However, in 30 percent of patients with diabetes, ...
Cached Medicine News:Health News:Pain of Denial Compared to Physical Pain 2
(Date:5/21/2013)... BURLINGTON, Mass. , May 21, 2013 ... leading research and advisory firms for pharmaceutical ... of an emerging agent on key efficacy ... disease progression, has the most influence over ... for advanced/metastatic hormone-receptor (HR-) positive, HER2-negative breast ...
(Date:5/21/2013)... CLARA, Calif. , May 21, 2013 ... game-changing embedded-ultrasound platform, today announced the introduction ... that allows complete network-based communications with all ... its latest embedded-ultrasound technology, including this new ... Sao Paulo, Brazil from ...
(Date:5/21/2013)... 21, 2013  The North Shore-LIJ Health System is ... hand-washing compliance at North Shore University Hospital in ... operating rooms at Forest Hills ... The new pilot program strengthens patient safety by ... (ORs), the first time in the US that remote ...
Breaking Medicine Technology:Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer 2Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 2North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 3North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 4
... June 1, 2011 Mirixa Corporation is pleased to ... licensing agreement for MirixaEdge(SM), a clinical application that supports ... Medication Therapy Management (MTM). Family Physicians Group (FPG), ... Source Pharmacy and selected it as FPG,s preferred pharmacy ...
... YORK, June 1, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0305172/Global-Intravenous-IV-Iron-Drugs-Industry.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ... Intravenous (IV) Iron Drugs in US$ Million. ...
Cached Medicine Technology:MirixaEdge(SM) to be Licensed by One Source Pharmacy, LLC 2MirixaEdge(SM) to be Licensed by One Source Pharmacy, LLC 3Global Intravenous (IV) Iron Drugs Industry 2Global Intravenous (IV) Iron Drugs Industry 3Global Intravenous (IV) Iron Drugs Industry 4Global Intravenous (IV) Iron Drugs Industry 5Global Intravenous (IV) Iron Drugs Industry 6Global Intravenous (IV) Iron Drugs Industry 7
Open blade design with aspiration capabilities for removing fluids from the operative site....
Pediatric model. Spring-controlled spread of blades with locking mechanism. Dull finish. Blades: 11 mm....
Fenestrated blades with screw-controlled spread. Dull finish. Blades: 15 mm....
Replacement snares for the E3525. 3 per package....
Medicine Products: